Elan leans on ISEQ losers
Shares at pharmaceutical company Elan tumbled 6% today after sales of its multiple sclerosis drug Tysabri came below expectations.
The stock led ISEQ-listed fallers with an overall decline of 92.61points at 9608.8.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





